MaxCyte, Inc. (MXCT) Gross margin 2019–2025
MaxCyte, Inc. (MXCT) gross margin by fiscal year — reported gross profit divided by reported revenue.
127.9%FY2025 · since FY2019: 144.2% → 127.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 127.9% | -14.0 pp |
| FY2024 | 141.9% | -45.5 pp |
| FY2023 | 187.4% | +51.2 pp |
| FY2022 | 136.2% | -4.0 pp |
| FY2021 | 140.2% | -11.2 pp |
| FY2020 | 151.5% | +7.2 pp |
| FY2019 | 144.2% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More MXCT financial trends
MXCT RevenueMXCT Net incomeMXCT Net marginMXCT Gross profitMXCT Operating incomeMXCT Operating marginMXCT Operating cash flowMXCT Free cash flowMXCT Capital expendituresMXCT Return on equityMXCT Stock buybacksMXCT Dividends paidMXCT Total assetsMXCT Total liabilitiesMXCT Shareholders’ equityMXCT overview →